ASCO Preview: Bristol PD-1 Data Spur Hopes For Double Immunotherapy
This article was originally published in Pharmaceutical Approvals Monthly
Immune checkpoint antibodies feature prominently in American Society of Clinical Oncology annual meeting program, showing promise in a range of cancers. Bristol showcases data for Yervoy in combination with its anti-PD-1 nivolumab in melanoma, while Roche unveils extensive early results for its anti-PD-L1 MPDL3280A.
You may also be interested in...
Bristol-Myers Squibb’s “anti-PD-1,” an antibody that gets between immune system T-cells out to destroy cancer cells and a cancer defense mechanism that would tie them up, caught the fancy of attendees at the American Society of Clinical Oncology annual meeting in Chicago with Phase I data indicating the drug could be safer and more effective than Bristol’s breakthrough immunotherapeutic for melanoma, Yervoy.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.